BRAF and melanoma: On the other hand, there is some evidence that ICI might be more effective in BRAF mutated melanomas compared to BRAF wildtype melanomas as the 5 year overall survival rate was 60% for BRAF mutant melanoma patients with combined ipilimumab and nivolumab therapy compared to 48% in BRAF wildtype patients as shown in the CheckMate 067 study (Hodi et al. 2018).